New Drugs, India-Style

Bahree, Megha
October 2009
Forbes Asia;10/5/2009, Vol. 5 Issue 15, p30
The article focuses on the efforts of Indian pharmaceutical company Glenmark Pharmaceuticals Ltd. in developing and marketing promising drugs. It states that Glenmark is focused on developing drugs that can treat diseases such as asthma, diabetes and multiple sclerosis. According to Glenn Saldanha, Glenmark's chief executive officer (CEO), the company's strategy is to develop promising compounds into early clinical stage and then license the developing and marketing rights for the U.S.


Related Articles

  • Glenmark Pharmaceuticals to Set up a New Manufacturing Facility in the US.  // World Energy News;7/17/2014, p3 

    The article reports that a manufacturing facility will be opened by pharmaceutical company Glenmark Pharmaceuticals Ltd. at North Carolina's Monroe Corporate Center. Glenn Saldanha, chairman at the company, states that the plan to set up the facility shows growth of the company and the U.S....

  • Glenmark Pharma. Subramanian, Anusha // Business Today;6/15/2008, Vol. 17 Issue 12, p116 

    The article presents the corporate profile for Glenmark Pharmaceuticals run by Glenn Saldanha in Mumbai, India. It was founded by Gracias Saldanha, father of Glenn, in 1977. Glenmark is among the few Indian firms with a successful drug discovery programme. According to Manoj Garg, a research...

  • Innovating to thrive.  // Business Today;12/21/2014, Vol. 23 Issue 25, p1 

    The article features Glenn Saldanha, Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Ltd., who is aiming to get a a new drug to the market and position Glenmark as an market innovation driven company.

  • Medicine's MAGIC Bullets? Lenzer, Jeanne // Discover;Jul2008, Vol. 29 Issue 7, p46 

    This article discusses how drugs that are presumed to be medical miracles can also have lethal consequences for patients who have adverse reactions. Medical studies on drugs can be misleading and can also be misinterpreted by doctors and the public alike. Additionally, the increase of new...

  • Vivus Crosses Obesity Finish Line, Starts Partner Race.  // Bioworld Week;9/14/2009, Vol. 17 Issue 37, p1 

    The article reports on the results of the two final Phase III trials of the obesity drug Qnexa from Mountain View, California based Vivus Inc. The company is noted to have tested Qnexa's low-dose and full-dose versions in morbidly obese patients and found out that patients' life improved....

  • FURTHER READING.  // PharmaWatch: CNS;Aug2007, Vol. 6 Issue 8, p26 

    A list of articles which discuss the latest development in the pharmaceutical sector is presented. They include a topic which features analysis of drugs that are designed to treat insomnia, an insight on the unmet needs in the depression market, and an assessment of the novel treatments for...

  • The Persevering Innovator. SHARMA, E. KUMAR // Business Today;10/2/2011, Vol. 20 Issue 20, p72 

    The article focuses on the innovative drive of Glenn Saldanha, chairman of Glenmark Pharmaceuticals Ltd. in Mumbai, India. He makes it a point to visit his research centre that serves as the hub of his focus on creating new chemical entities (NCE). He spends most of his time in thinking about...

  • United States : GLENMARK PHARMACEUTICALS plans to construct first manufacturing plant in the US.  // TendersInfo News;8/7/2014, p1 

    The article focuses on the plan of Glenmark Pharmaceuticals to construct a facility for oral solid dosage manufacturing in North Carolina. Company's chairman Glenn Saldanha states that the plan will set up a new state-of-the-art manufacturing facility, reflecting the growth of the company. It...

  • Glenmark Conferred Civic Award 2013-14 for Social Development by the Bombay Chamber of Commerce and Industry.  // World Energy News;9/25/2014, p21 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics